Latest Earnings Results: Q2 '27
Estimated EPS
---
Reported EPS
-$0.08
Surprise
---
Estimated Rev
---
Reported Rev
$0.42M
Surprise
---
$RNXT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.09 down -12.50% YoY • Reported revenue of $0.56M up 185.79% YoY • RenovoRx expects to close enrollment for its Phase III TIGER-PaC trial by June 2026, with final data anticipated in mid to late 2027. RenovoRx also expects RenovoCath sales revenue to grow sequentially for the remainder of 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '27. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '27 | -- | -$0.08 | -- | N/A |
Q1 '27 | -- | -$0.08 | -- | N/A |
Q2 '26 | -$0.07 | -- | -- | N/A |
Q1 '26 | -$0.08 | -$0.09 | -12.50% | MISSED |
Q4 '25 | -$0.08 | -$0.08 | -- | EXPECTED |